Preoperative lapatinib plus trastuzumab elicits response in HER2-positive breast cancer
Addition of lapatinib to trastuzumab improves responses in women with newly diagnosed, HER2-positive breast cancer who receive the combination prior to undergoing surgery, suggests research. (Source: MedWire News)
Source: MedWire News - March 15, 2016 Category: Consumer Health News Tags: Breast cancer Source Type: news

New agent overcomes drug resistance in HER2-positive breast cancer preclinical study shows
(Dana-Farber Cancer Institute) A type of breast cancer that often develops resistance to targeted therapies was driven back into remission in mice by a drug that blocks the division of cancer cells, a new study led by researchers at Dana-Farber Cancer Institute has found. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 14, 2016 Category: Cancer & Oncology Source Type: news

New Agent Overcomes Drug Resistance in HER2-Positive Breast Cancer, Preclinical Study Shows (Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center)
A type of breast cancer that often develops resistance to targeted therapies was driven back into remission in mice by a drug that blocks the division of cancer cells, a new study led by researchers at Dana-Farber Cancer Institute has found. The results, reported in Cancer Cell, prompted investigators to launch a clinical trial of the new agent in women with a metastatic form of this cancer, known as HER2-positive breast cancer. Dana-Farber/Brigham and Women's Cancer Center | Massachusetts Ge... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - March 14, 2016 Category: Cancer & Oncology Source Type: news

Medical News Today: Cancer breakthrough? Drug combo eradicated breast cancer tumors in 11 days
A cancer drug duo eliminated tumors for some women with HER2-positive breast cancer in only 11 days, while others saw a significant reduction in tumor size, new research reveals. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 11, 2016 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Herceptin plus tykerb makes breast cancer tumours 'disappear'
Results of a clinical trial of patients with HER2-positive breast cancer were presented at the European Breast Cancer Conference in Amsterdam. Patients treated with a combination of herceptin plus lapatinib showed significantly decreased tumour mass. The Independent (Source: Society for Endocrinology)
Source: Society for Endocrinology - March 11, 2016 Category: Endocrinology Source Type: news

Drug Duo May Rapidly Shrink Breast Tumors in Some Patients
Researchers say combo therapy worked well for about 1 in 4 women with HER2-positive breast cancer (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - March 11, 2016 Category: Cancer & Oncology Source Type: news

Drug combo shrinks HER2 breast cancers 'within 11 days'
A drug combination taken before surgery shrinks and may even destroy tumours in women with HER2 positive disease within 11 days, a UK trial has found. (Source: Nursing Times)
Source: Nursing Times - March 11, 2016 Category: Nursing Source Type: news

Drug Duo May Rapidly Shrink Breast Tumors in Some
Researchers say combo therapy worked well for about 1 in 4 women with HER2-positive breast cancer (Source: WebMD Health)
Source: WebMD Health - March 10, 2016 Category: Consumer Health News Source Type: news

Drug Duo May Rapidly Shrink Breast Tumors in Some Patients
Researchers say combo therapy worked well for about 1 in 4 women with HER2-positive breast cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 10, 2016 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Gynecology, Nursing, Oncology, Pharmacy, News, Source Type: news

Drug Duo May Rapidly Shrink Breast Tumors in Some Patients
Researchers say combo therapy worked well for about 1 in 4 women with HER2-positive breast cancer (Source: U.S. News - Health)
Source: U.S. News - Health - March 10, 2016 Category: Consumer Health News Source Type: news

Drug Duo May Rapidly Shrink Breast Tumors in Some Patients
Researchers say combo therapy worked well for about 1 in 4 women with HER2-positive breast cancer Source: HealthDay Related MedlinePlus Page: Breast Cancer (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - March 10, 2016 Category: Consumer Health News Source Type: news

Drug Duo May Rapidly Shrink Breast Tumors in Some Patients
THURSDAY, March 10, 2016 -- A two-drug combo quickly shrinks certain breast cancer tumors before surgery or chemotherapy in some women, British researchers report. The specific breast cancer is called human epidermal growth factor receptor 2 (HER2)... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 10, 2016 Category: Journals (General) Source Type: news

Lapatinib and trastuzumab shrinks HER2+ breast cancer in 11 days after diagnosis
(ECCO-the European CanCer Organisation) Approximately one-quarter of women with HER2 positive breast cancer, who were treated with a combination of two targeted drugs before surgery and chemotherapy, saw their tumors shrink significantly or even disappear, according to results from the UK EPHOS-B clinical trial involving 257 women with newly-diagnosed, operable HER2 positive disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 10, 2016 Category: Cancer & Oncology Source Type: news

Spectrum begins Phase II trial of Poziotinib to treat breast cancer
US-based Spectrum Pharmaceuticals has begun a Phase II clinical trial of its new pan-HER inhibitor, Poziotinib, for patients with HER2-positive metastatic breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - March 8, 2016 Category: Pharmaceuticals Source Type: news

SMC denies NHS Scotland access to Perjeta breast cancer drug
The Scottish Medicines Consortium (SMC) has not recommended the use of targeted medicine, Perjeta, in NHS Scotland as a neoadjuvant (pre-surgery) treatment for patients with early-stage, HER2-positive breast cancer. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 8, 2016 Category: Pharmaceuticals Source Type: news

AstraZeneca's Faslodex receives FDA approval for new indication
AstraZeneca has received approval from the US Food and Drug Administration (FDA) for a new indication of its Faslodex (fulvestrant) to treat women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advance… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 7, 2016 Category: Pharmaceuticals Source Type: news

Drug instigates strong immune response in certain breast cancers
Stephen FellerCLEVELAND, Feb. 29 (UPI) -- A single dose of the drug trastuzumab initiated a stronger immune response in one subtype of HER2-positive breast cancer tumors, according to a study. (Source: Health News - UPI.com)
Source: Health News - UPI.com - February 29, 2016 Category: Consumer Health News Source Type: news

Single dose of trastuzumab kick starts immune response in certain breast cancers
(Case Western Reserve University) A tumor's immune response to a single dose of the HER2 inhibitor trastuzumab predicted which patients with HER2-positive breast cancer would respond to the drug on a more long-term basis, according to the results of a study published recently in Clinical Cancer Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 29, 2016 Category: Cancer & Oncology Source Type: news

Relationship Between HER2 Expression and Trastuzumab BenefitRelationship Between HER2 Expression and Trastuzumab Benefit
Will your patient benefit from trastuzumab? New research using quantitative RNA analysis of HER2 may help you find out. Breast Cancer Research (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - February 26, 2016 Category: Pathology Tags: Hematology-Oncology Journal Article Source Type: news

Treating HER2 Lung Cancers: The EUHER2 CohortTreating HER2 Lung Cancers: The EUHER2 Cohort
Is trastuzumab beneficial in combination with chemotherapy for advanced HER2-positive advanced NSCLC? Annals of Oncology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - February 26, 2016 Category: Pathology Tags: Hematology-Oncology Journal Article Source Type: news

PharmaMar initiates a Phase II trial with antitumor drug PM184 in advanced breast cancer
(Pharmamar) PharmaMar has announced the start of an open-label multi-center two-stage Phase II trial with the anti-tumor drug PM184. The trial will be conducted in 10 European clinical centers and will include 106 patients. The trial will focus on patients with hormone-receptor positive, HER2-negative, locally advanced and/or metastatic breast cancer, who have experienced progression following earlier treatment with anthracyclines and taxanes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 26, 2016 Category: Cancer & Oncology Source Type: news

Pfizer Receives Expanded FDA Approval For Ibrance (palbociclib) In HR+, HER2- Metastatic Breast Cancer
Friday, February 19, 2016 -- Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of Ibrance (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 20, 2016 Category: Drugs & Pharmacology Source Type: news

Lost in Translation
She was dying. Diagnosed with invasive colon cancer at age 41 and having undergone many unsuccessful interventions, Mrs. B, a police dispatcher and mother of two, came to us with hopes that an experimental therapy might find her cancer's Achilles' heel. I was 23. I had just finished my first year of medical school and landed a summer gig on a clinical trials team at a prestigious cancer center. My previous research occurred entirely in the laboratory, where cancer existed only through the lens of a microscope or the label "Ca" on a test tube. But now, cancer had a face. If she met all of the criteria, Mrs. B wo...
Source: Healthy Living - The Huffington Post - February 18, 2016 Category: Consumer Health News Source Type: news

Impact of Updated HER2 Testing Guidelines in Breast CancerImpact of Updated HER2 Testing Guidelines in Breast Cancer
Are the ASCO/CAP updated clinical practice guidelines for HER2 testing in breast cancer a significant improvement over the prior FDA guidelines? Modern Pathology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - February 4, 2016 Category: Pathology Tags: Pathology & Lab Medicine Journal Article Source Type: news

On World Cancer Day: BCRF Calls to Unite Around Research
All normal cells grow and divide. But cancer cells grow without limit. They divide without stopping. They change and they spread, invading healthy tissues. And all too often, they're lethal. On World Cancer Day, we have a very simple message: to overpower a disease that thrives on dividing, we must unite around research. Cancer knows no age, gender or race. It has no boundaries. As cancer's toll grows around the world, it is becoming just as much a threat to global health and development as infectious diseases. According to the World Health Organization more people die from cancer than from AIDS, malaria and tuberculosis ...
Source: Science - The Huffington Post - February 3, 2016 Category: Science Source Type: news

Trastuzumab emtansine saves costs in HER2+ mBC
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2016 Category: Drugs & Pharmacology Source Type: news

In lung cancer, not all HER2 alterations are created equal
Study shows two distinct causes of HER2 activation in lung cancer: mutation of the gene and amplification of the gene. In patient samples of lung adenocarcinoma, 3 percent were found to have HER2 amplification and another 3 percent were found to have HER2 mutation. No samples were found to have both. These distinct causes of HER2 positivity imply the use of different targeted therapies to combat these related but possibly distinct diseases. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 28, 2016 Category: Science Source Type: news

In lung cancer, not all HER2 alterations are created equal
(University of Colorado Anschutz Medical Campus) Study shows two distinct causes of HER2 activation in lung cancer: mutation of the gene and amplification of the gene. In patient samples of lung adenocarcinoma, 3 percent were found to have HER2 amplification and another 3 percent were found to have HER2 mutation. No samples were found to have both. These distinct causes of HER2 positivity imply the use of different targeted therapies to combat these related but possibly distinct diseases. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 28, 2016 Category: Cancer & Oncology Source Type: news

ALTTO No More Than a Detour for HER2+ Breast CancerALTTO No More Than a Detour for HER2+ Breast Cancer
Dr Lidia Schapira weighs in on the results of the ALTTO trial in HER2-positive breast cancer in which dual therapy using trastuzumab plus lapatinib proved disappointing. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 25, 2016 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news

Asian women with endocrine-resistant breast cancer benefit from combination therapy
(European Society for Medical Oncology) Data collected in Japanese and Korean patients included in the global PALOMA3 trial provides evidence that combining palbociclib with fulvestrant is an effective strategy to overcome endocrine resistance in women with hormone receptor positive, HER2 negative advanced breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 18, 2015 Category: Cancer & Oncology Source Type: news

Asian women with endocrine-resistant breast cancer benefit from combination therapy
(European Society for Medical Oncology) Data collected in Japanese and Korean patients included in the global PALOMA3 trial provides evidence that combining palbociclib with fulvestrant is an effective strategy to overcome endocrine resistance in women with hormone receptor positive (HR+), HER2 negative (HER2-) advanced breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 18, 2015 Category: Cancer & Oncology Source Type: news

Herceptin Affirmed, Anthracyclines Questioned in Major TrialHerceptin Affirmed, Anthracyclines Questioned in Major Trial
The landmark BIRCG-006 trial that helped establish trastuzumab as a standard for early-stage HER2-positive breast cancer continues to stir debate over which chemotherapy to pair it with. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 17, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Jury Still Out on Anthracyclines in HER2+ Breast CancerJury Still Out on Anthracyclines in HER2+ Breast Cancer
Dr Sara Tolaney highlights studies in HER2-positive breast cancer from SABCS 2015, including the less-than-definitive 10-year results of the BCIRG 006 study. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 15, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

Solidified: TDM-1 in Pretreated Metastatic HER2-+ PatientsSolidified: TDM-1 in Pretreated Metastatic HER2-+ Patients
The final overall survival results from a major trial of patients with heavily pretreated disease are now in. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Experts Gather for International Breast Cancer Research Conference
Breast cancer specialists from all over the world head to Texas this week for the annual San Antonio Breast Cancer Symposium (SABCS). Now in its 38th year, the conference showcases the latest in breast cancer research. The event, which runs from December 8th through the 12th, is co-sponsored by the Cancer Therapy and Research Center at the University of Texas Health Science Center at San Antonio, the American Association for Cancer Research (AACR), and the Baylor College of Medicine. Get the headlines from the conference from our content partners at CURE.  December 13, 2015Kadcyla Extends Survival in Heavily Pretreate...
Source: American Cancer Society :: News and Features - December 14, 2015 Category: Cancer & Oncology Tags: Breast Cancer Source Type: news

T-DM1 improved overall survival for heavily pretreated patients with HER2-pos breast cancer
Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy (trastuzumab [Herceptin] and lapatinib [Tykerb]), median overall survival was increased for those treated with trastuzumab emtansine (T-DM1 [Kadcyla]) compared with those who received treatment of physician's choice, according to results from the phase III TH3RESA clinical trial. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 11, 2015 Category: Science Source Type: news

T-DM1 improved overall survival for heavily pretreated patients with HER2-positive breast cancer
(American Association for Cancer Research) Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy (trastuzumab [Herceptin] and lapatinib [Tykerb]), median overall survival was increased for those treated with trastuzumab emtansine (T-DM1 [Kadcyla]) compared with those who received treatment of physician's choice, according to results from the phase III TH3RESA clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2015 Category: Cancer & Oncology Source Type: news

A 'Major, Major Finding' in Managing Residual Breast Cancer A 'Major, Major Finding' in Managing Residual Breast Cancer
The addition of capecitabine to standard care for HER2-negative breast cancer patients with residual invasive disease after neoadjuvant chemo and surgery improved disease-free and overall survival. Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - December 10, 2015 Category: Surgery Tags: Hematology-Oncology News Source Type: news

SABCS15: Promising phase 1 results lead to phase 2 for ONT-380 in HER2+ breast cancer
(University of Colorado Anschutz Medical Campus) Results of an ongoing phase 1b clinical trial presented today at the 2015 San Antonio Breast Cancer Symposium show promise of the experimental anti-cancer agent ONT-380 against metastatic HER2+ breast cancer, especially against brain metastases commonly associated with progression of the disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 9, 2015 Category: Global & Universal Source Type: news

Biomarker Driven Strategy for ER+/HER2- Invasive Breast CancerBiomarker Driven Strategy for ER+/HER2- Invasive Breast Cancer
Find out more about what's behind the design of the ALTERNATE Trial. Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 3, 2015 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Neoadjuvant use of pertuzumab in HER2-positive breast cancer: Hint of lesser benefit
(Institute for Quality and Efficiency in Health Care) In contrast to the use in advanced unresectable breast cancer, no positive effects have been proven. However, more patients discontinue treatment, particularly due to cardiac disorders. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 3, 2015 Category: Global & Universal Source Type: news

Tykerb –Lapatinib - A Targeted Biologic...
Tykerb (lapatinib) is a targeted biologic therapy given as treatment for HER2 positive metastatic breast cancer. Tykerb can be taken with Xeloda, another oral chemotherapy drug, to extend survival and prevent the progression of advanced breast cancer. Read about how Tykerb works, possible side effects and drug interactions. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - November 29, 2015 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Dual HER2 Inhibition Flops as Adjuvant Breast Ca Tx (CME/CE)
(MedPage Today) -- Lapatinib-trastuzumab no better than trastuzumab alone (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 23, 2015 Category: Hematology Source Type: news

New Studies Investigating the Use of KEYTRUDA® (pembrolizumab) Across Solid and Hematological Cancers to Be Presented at Upcoming Congresses
Dateline City: KENILWORTH, N.J. First-Time Presentation of KEYTRUDA Compared to Chemotherapy in Advanced Non-Small Cell Lung Cancer From KEYNOTE-010 Study New Findings of KEYTRUDA in Novel Combinations with Other Immunotherapies in Advanced Melanoma First-Time Findings in Multiple Myeloma and ER-Positive/HER2-Negative Breast Cancer as Well as New Findings in Classical Hodgkin Lymphoma KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that data investigating t...
Source: Merck.com - Corporate News - November 17, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD NYSE:MRK Source Type: news

Why FDA should oversee laboratory developed tests
By: Peter Lurie, M.D., M.P.H. Today FDA is issuing a report that illustrates the real and potential harms to patients and to public health from certain laboratory developed tests (LDTs) – tests that are designed, manufactured and used in a single laboratory. When FDA first began regulating medical devices under the Medical Device Amendments in the 1970s, we chose not to enforce applicable regulatory requirements for LDTs because they were relatively simple tests generally confined to local labs, and often used for rare conditions. But times have changed. LDTs have increased in complexity and availability and are now ...
Source: Mass Device - November 17, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Blog FDA Source Type: news

Medtech approvals: FDA releases September 2015 PMAs
The FDA today released its list of the pre-market approvals it granted for medical devices in September 2015: Summary of PMA Originals & Supplements Approved Originals: 4 Supplements: 53 Summary of PMA Originals Under Review Total Under Review: 55 Total Active: 31 Total On Hold: 24 Summary of PMA Supplements Under Review Total Under Review: 611 Total Active: 461 Total On Hold: 150 Summary of All PMA Submissions Originals: 3 Supplements: 84 Summary of PMA Supplement PMA Approval/Denial Decision Times Number of Approvals: 53 Number of Denials: 0 Average Days Fr Receipt to Decision (Total Time): 127.6 FDA Ti...
Source: Mass Device - November 16, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Regulatory/Compliance Source Type: news

Rare Her2 mutations may not always spur breast cancers on their own
(Johns Hopkins Medicine) Results of a new laboratory study by Johns Hopkins Kimmel Cancer Center researchers suggests that some rare 'missense' mutations in the HER2 gene are apparently not -- on their own -- capable of causing breast cancer growth or spread. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 10, 2015 Category: Cancer & Oncology Source Type: news

PharmaMar's novel ADC demonstrates anticancer activity in HER2-expressing
(Pharmamar) PharmaMar announced that its novel Antibody-Drug Conjugate (ADC) demonstrates strong anticancer activity in vitro and in vivo against tumors expressing HER2 derived from breast, gastric and ovarian cancers. The novel ADC MI130004 consists of a new marine-derived tubulin inhibitor that is covalently bound to the HER2 antibody trastuzumab via a non-hydrolysable linker. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 6, 2015 Category: Global & Universal Source Type: news

Ovarian cancer drug 'can help with some types of prostate cancer'
Conclusion Prostate cancer is common in the UK, so news of new treatment options is always welcome. However, this study does not show for certain that olaparib works better than no treatment, even for men with the DNA repair mutations identified in the study as responding to treatment. The first problem is the lack of a comparison group. We can see what happened to the men who took the drug, but not what might have happened if they had not taken it, or if they'd taken another type of treatment not already tried. And most of the men treated did not get any benefit from the drug. Only 16 of the 49 men assessed showed any s...
Source: NHS News Feed - October 29, 2015 Category: Consumer Health News Tags: Cancer Medication Older people Source Type: news

MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA® (pembrolizumab) for Advanced Gastric Cancer
Dateline City: ROCKVILLE, Md. and KENILWORTH, N.J. Clinical trial to evaluate MacroGenics' Fc-optimized anti-HER2 antibody with Merck's anti-PD-1 therapy in patients with advanced HER2-positive gastric cancer ROCKVILLE, Md.and KENILWORTH, N.J. Language: English read more (Source: Merck.com - Product News)
Source: Merck.com - Product News - October 22, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news